Clinical trial results presented for the first time today at the Union World Conference on Lung Health revealed evidence to support the use of four new, improved regimens to treat multi-drug resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB). The team—led by Doctors Without Borders/Médecins Sans Frontières (MSF), Partners In Health (PIH), and Interactive Research and Development […]
Read More… from Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options